PfGLURP as LSP
Development of a Plasmodium falciparum vaccine based on long synthetic peptide derived from GLURP, a merozoite surface antigen targeted by biologically active human antibodies.
An Open Randomised, Two Adjuvant, Three Doses Safety and Immunogenicity Clinical trial was conducted in Nijmegen.
The results are published in Vaccine 25 issue 15 (2007) 2930-2940, which can be accessed free by subscribers to ScienceDirect (www.sciencedirect.com)